Associated Risk of Recombinant Activated Factor VIIa Application
DOI:
https://doi.org/10.1532/HSF98.20121127Abstract
Background: The recombinant human coagulation FVIIa was approved for the treatment of bleeding in hemophilia patients. The reports of a good hemostatic effect were followed by studies and applications without a regulatory extension of the therapeutic indication (off-label use). The aim of this retrospective study is the evaluation of thromboembolic adverse events and side effects in a large cohort of patients with FVIIa therapy.
Methods: In the period from January 2009 to March 2011, a total of 143/2453 (5.8%) cardiac surgical patients (69% male; age 67 ± 11 years; 39% thoracic aorta) were treated with different doses (mean, 6.1 mg; range, 1 to 27.2 mg) of factor VIIa. The administration of FVIIa was seen as a last therapeutic option and administered at the end of the treatment algorithm for severe bleeding.
Results: Due to an acute bleeding situation in 143 patients, 7.9 ± 5.8 units of packed red blood cells, 9.5 ± 6.1 units of fresh frozen plasma, 1740 ± 1860 IU PPSB (Prothrombin-Proconvertin-Stuart Factor-Antihemophilic Factor B), 5.6 ± 4 g fibrinogen, and 7.9 ± 7.6 units of platelets were administered. A re-thoracotomy was necessary, despite maximal procoagulant therapy, in 55% of patients. The in-hospital mortality was 36% (51/2453 = 2%). Thrombotic complications occurred with a frequency of 16% (mesenteric infarction, n = 9; stroke/transient ischemic attack, n = 3; myocardial infarction, n = 3; other, n = 8).
Conclusion: The proof of direct causality of the events in relation to the administration of FVIIa is difficult because the temporal and therapeutic relationships with concomitant vasoconstrictive and procoagulant therapies were not obvious. However, there remains a suspicion that a higher rate of mesenteric infarctions may be provoked by the administration of FVIIa.
References
Boffard KD, Riou B, Warren B, et al. 2005. Recombinant Factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59:8-5.nBui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. 2002. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 124:852-4.nDietrich W, Spannagl M. 2002. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anaesth Analg 94:1369-70.nDiprose P, Herbertson MJ, O'Shaughnessy D, Deakin CD, Gill RS. 2005. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. Br J Anaesth 94:271-8.nEngoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. 2002. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 74:1180-6.nFriedrich PW, Levi M, Bauer KA, et al. 2001. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 103:2555-9.nGoodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. 2004. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 44:1325-31.nHay CR, Negrier C, Ludlam CA. 1997. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 78:1463-7.nHedner U, Kisiel W. 1983. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 71:1836-41.nHoffman M, Monroe DM 3rd. 2001. A cell-based model of hemostasis. Thromb Haemost 85:958-65.nJámbor C, Bremerich D, Moritz A, Seifried E, Zwissler B. 2008. Management of hemostasis disorders after extracorporeal circulation. A clinical therapy algorithm [in German]. Anaesthesist 57:374-81.nJurlander B, Thim L, Klausen NK, et al. 2001. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 27:373-84.nKarkouti K, Beattie WS, Wijeysundera DN, e al. 2005. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 45:26-34.nKenet G, Walden R, Eldad A, Martinowitz U. 1999. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354:1879.nKeogh B, Kinsman R. 2004. Fifth National Adult Cardiac Surgical Database Report 2003: Improving Outcomes for Patients. Reading, Massachusetts: Society of Cardiothoracic Surgeons of Great Britain and Ireland, Dendrite Clinical Systems Ltd.nKoch CG, Khandwala F, Li L, Estafanous FG, Loop FD, Blackstone EH. 2006. Persistent effect of red cell transfusion on health-related quality of life after cardiac surgery. Ann Thorac Surg 82:13-20.nKoch CG, Li L, Duncan AI, et al. 2006. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 34:1608-16.nLevi M, Levy JH, Andersen HF, Truloff D. 2010. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363:1791-800.nMcGill N, O'Shaughnessy D, Pickering R, Herbertson M, Gill R. 2002. Mechanical methods of reducing blood transfusion in cardiac surgery: randomised controlled trial. BMJ 324:1299.nMurphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. 2007. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 116:2544-52.nNuttall GA, Oliver WC, Ereth MH, et al. 2000. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology 92:674-82.nO'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. 2006. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295:293-8.nVeldman A, Hoffman M, Ehrenforth S. 2003. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 10:797-811.nWoodman RC, Harker LA. 1990. Bleeding complications associated with cardiopulmonary bypass. Blood 76:1680-97.nYank V, Tuohy CV, Logan AC, et al. 2011. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 154:529-40.n
